Eye‐Targeted A20 Gene Therapy Alleviates Ischemic Retinopathy by Reducing Pathologic Neovascularization, Gliosis, and Neuronal Apoptosis
The FASEB Journal · 2025
DOI: 10.1096/fj.202500419r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Sanah Essayagh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Division of Vascular and Endovascular Surgery and the Center for Vascular Biology Research, Beth Israel Deaconess Medical …. Hauptthemen laut MEDLINE: Apoptosis, Genetic Therapy, Gliosis, Tumor Necrosis Factor alpha-Induced Protein 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Juvenile Diabetes Research Foundation, NHLBI NIH HHS, NIH R01.
Abstract (Originalsprache)
Intravitreal administration of anti‐VEGF therapies has been highly beneficial in treating ischemic proliferative retinopathies (PR). However, a quarter of patients do not benefit from these therapies due to primary or secondary non‐response and adverse side effects. The limited success of anti‐VEGF therapies underscores the complex interplay between the various pathogenic contributors to this disease. Mechanistic studies have emphasized the importance of pathologic angiogenesis, reactive inflammatory gliosis, and heightened neuronal apoptosis as key determinants of disease outcomes. We surmise that therapeutic strategies targeting all three components would be highly valuable. Through gain and loss‐of‐function studies of A20/TNFAIP3, a ubiquitous NF‐κB inhibitor with established cytoprotective functions in endothelial and neuronal cells, we uncovered a novel function for this gene as a physiologic regulator of angiogenesis in human retinal endothelial cell cultures. In vivo, intravitreal delivery of an A20 gene therapy, which yields transgene expression throughout retinal layers, significantly reduces central vaso‐obliteration and pathological peripheral neovascular tuft formation in a mouse model of oxygen‐induced PR. In contrast, mice with total or partial A20 knockdown exhibited worse lesions. Remarkably, A20‐related benefits were associated with a significant reduction in inflammatory gliosis and improved glial function, notably in Müller cells, as evaluated by glial fibrillary acid protein (GFAP) and glutamine synthetase (GS) immunostaining, and with decreased apoptotic cell death across the retina, including in neuronal cells. Conversely, A20 knockdown aggravated these features. By concurrently reducing pathologic neovascularization, reactive gliosis, and neuronal apoptosis in the retina, A20 emerges as a unique therapeutic target with promising translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Division of Vascular and Endovascular Surgery and the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- The Eye Unit, Joslin Diabetes Center, Boston, Massachusetts, USA.
- The Transplant Institute and the Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Christiane Ferran
Förderung
- Juvenile Diabetes Research Foundation
- NHLBI NIH HHS
- NIH R01
- JDRF
- National Heart, Lung, and Blood Institute
Zitieren
APA
Essayagh, S., Aridi, T., Turunen, T., Choi, L., Adam, H., Patel, N., Scali, S. T., Fisher, M. D., Skaf, K., Csizmadia, E., Brennan, P., Sadek, A., Skaf, J., Zhan, M., Hansen, E., Shamloo, M., DeStefino, N. R., Clermont, A. C., Angolano, C., & Ferran, C. (2025). Eye‐Targeted A20 Gene Therapy Alleviates Ischemic Retinopathy by Reducing Pathologic Neovascularization, Gliosis, and Neuronal Apoptosis. The FASEB Journal. https://doi.org/10.1096/fj.202500419r
Vancouver
Essayagh S, Aridi T, Turunen T, Choi L, Adam H, Patel N, et al. Eye‐Targeted A20 Gene Therapy Alleviates Ischemic Retinopathy by Reducing Pathologic Neovascularization, Gliosis, and Neuronal Apoptosis. The FASEB Journal. 2025. doi:10.1096/fj.202500419r
BibTeX
@article{Essayagh2025,
author = {Essayagh, Sanah and Aridi, Tarek and Turunen, Tytteli and Choi, Lynn and Adam, Hugo and Patel, Nyah and Scali, Salvatore T and Fisher, Mark D and Skaf, Karl and Csizmadia, Eva and Brennan, Phillip and Sadek, Anthony and Skaf, Jona and Zhan, Michelle and Hansen, Emily and Shamloo, Maryam and DeStefino, Nicholas R and Clermont, Allen C and Angolano, Cleide and Ferran, Christiane},
title = {Eye‐Targeted A20 Gene Therapy Alleviates Ischemic Retinopathy by Reducing Pathologic Neovascularization, Gliosis, and Neuronal Apoptosis},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500419r}
}
EUVIMED